{"classes":[{"categories":[{"measurements":[{"comment":"NA = Median, upper limit, lower limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG001","lowerLimit":"3.8","upperLimit":"NA","value":"28.9"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG003","lowerLimit":"5.6","upperLimit":"NA","value":"14.5"},{"comment":"NA = Median, upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG004","lowerLimit":"6.0","upperLimit":"NA","value":"NA"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG005","lowerLimit":"6.9","upperLimit":"NA","value":"10.1"},{"groupId":"OG006","lowerLimit":"25.1","upperLimit":"25.1","value":"25.1"},{"groupId":"OG007","lowerLimit":"7.4","upperLimit":"15.9","value":"12.0"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG008","lowerLimit":"34.4","upperLimit":"NA","value":"37.0"},{"comment":"NA = Upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG009","lowerLimit":"17.5","upperLimit":"NA","value":"68.5"},{"groupId":"OG010","lowerLimit":"4.1","upperLimit":"7.5","value":"5.4"},{"groupId":"OG011","lowerLimit":"3.9","upperLimit":"3.9","value":"3.9"},{"comment":"NA = Median, upper limit, lower limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG012","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG013","lowerLimit":"3.7","upperLimit":"44.4","value":"12.0"},{"groupId":"OG014","lowerLimit":"4.6","upperLimit":"20.3","value":"8.4"},{"groupId":"OG015","lowerLimit":"3.5","upperLimit":"20.6","value":"3.9"},{"groupId":"OG016","lowerLimit":"4.8","upperLimit":"34.0","value":"15.0"},{"groupId":"OG017","lowerLimit":"8.3","upperLimit":"22.8","value":"15.6"},{"groupId":"OG018","lowerLimit":"12.4","upperLimit":"12.4","value":"12.4"},{"groupId":"OG019","lowerLimit":"13.5","upperLimit":"31.4","value":"14.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"8"},{"groupId":"OG013","value":"5"},{"groupId":"OG014","value":"3"},{"groupId":"OG015","value":"3"},{"groupId":"OG016","value":"7"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"3"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per modified RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per modified RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. DOR assessments were based on investigator with confirmation. The DOR according to modified RECIST 1.1 for all participants who experienced a confirmed CR or PR was reported. Per protocol, participants were analyzed according to disease type.","dispersionType":"Full Range","groups":[{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with colon or rectal adenocarcinoma.","id":"OG000","title":"Cohort A1: Colon or Rectal Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with anal canal squamous cell carcinoma.","id":"OG001","title":"Cohort A2: Anal Canal Squamous Cell Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with Pancreas Adenocarcinoma.","id":"OG002","title":"Cohort A3: Pancreas Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with esophageal squamous cell carcinoma or adenocarcinoma (including gastroesophageal (GE) junction).","id":"OG003","title":"Cohort A4: Esophageal Squamous Cell Carcinoma or Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with biliary tract adenocarcinoma (gallbladder and biliary tree, but excluding ampulla of vater cancers).","id":"OG004","title":"Cohort A5: Biliary Tract Adenocarcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with carcinoid tumors.","id":"OG005","title":"Cohort A6: Carcinoid Tumors"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with neuroendocrine carcinomas (well or moderately differentiated pancreatic neuroendocrine tumor).","id":"OG006","title":"Cohort A7: Neuroendocrine Carcinomas"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with ER positive HER2 negative breast cancer.","id":"OG007","title":"Cohort B1: ER Positive HER2 Negative Breast Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with ovarian epithelial, fallopian tube or primary peritoneal carcinoma.","id":"OG008","title":"Cohort B2: Ovarian Epithelial, Fallopian Tube or Primary Peritoneal Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled endometrial carcinoma.","id":"OG009","title":"Cohort B3: Endometrial Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled cervical squamous cell cancer.","id":"OG010","title":"Cohort B4: Cervical Squamous Cell Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with vulvar squamous cell carcinoma.","id":"OG011","title":"Cohort B5: Vulvar Squamous Cell Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with small cell lung cancer.","id":"OG012","title":"Cohort C1: Small Cell Lung Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with mesothelioma (malignant pleural mesothelioma).","id":"OG013","title":"Cohort C2: Mesothelioma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with thyroid cancer (papillary or follicular subtype).","id":"OG014","title":"Cohort D1: Thyroid Cancer"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with salivary gland carcinoma.","id":"OG015","title":"Cohort D2: Salivary Gland Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with nasopharyngeal carcinoma.","id":"OG016","title":"Cohort D3: Nasopharyngeal Carcinoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with glioblastoma multiforme.","id":"OG017","title":"Cohort E1: Glioblastoma Multiforme"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with leiomyosarcoma.","id":"OG018","title":"Cohort E2: Leiomyosarcoma"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \\~2 years. This cohort represents all participants who enrolled with prostate adenocarcinoma.","id":"OG019","title":"Cohort E3: Prostate Adenocarcinoma"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all participants who received at least 1 dose of study treatment, had a baseline scan with measurable disease per modified RECIST 1.1, had the intended indication, and experienced a response. Per protocol-specified definition, DOR could not be analyzed in arms which did not have a confirmed response of CR or PR.","reportingStatus":"POSTED","timeFrame":"Up to approximately 86 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}